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Abstract The presence of DNA and RNA circulating in
human plasma and serum is described. The known sources
of the DNA/RNA in blood, the ability of these nucleic acids
to enter other cells and to express in the recipient cells are
considered along with their relationship to metastases. The
possible role(s) of the DNA/RNA in personalized clinical
diagnosis, monitoring of treatment and prognosis in
oncology are discussed.
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Introduction
Although DNA was first demonstrated in human blood in
1948 [1] with blood from healthy donors, pregnant women
and clinical patients, the information was not exploited until
much later. This information disappeared from view during
the major research effort of that period to understanding the
chemical nature of the gene, and in particular, the structure
of DNA that was still to be determined [2, 3] as was its
identification as the gene [4]. Much later, high DNA levels
were demonstrated in the blood of patients with systemic lupus
erythematosus [5, 6] with similar observations following for a
range of illnesses [7–10] as well as in cancer patients [10].
Differences were demonstrable between those cancer patients
with primary tumors only and those with metastases [11].
Extraction and purification of the DNA from cancer patients
subsequently showed it to be tumor cell derived [12].
This review will consider some aspects of the biology of
DNA/RNA found in blood, but the main focus will be on
the possible role(s) of circulating nucleic acids in plasma
and serum (CNAPS) in personalized cancer diagnosis,
monitoring of treatment and prognosis.
The source of CNAPS
Both DNA and RNA are present in CNAPS with 1.8–35 ng
DNA ml−1 serum and 2.5 ng RNA ml−1 serum being found
in healthy individuals by various analytical methods [13–
15]. Such nucleic acids are derived from a variety of
sources in the case of those found in plasma and serum and
on entering recipient cells they can modify the biology of
those cells [16]. The sources for such nucleic acids in
plasma and serum include (a) breakdown of blood cells; (b)
bacteria and viruses, (c) leukocyte surface DNA, (d) cell
and tissue necrosis, (e) apoptotic release of nucleosomes, (f)
cellular release of exosomes, (g) transposons and retro-
transposons and (h) spontaneous release of a newly
synthesized DNA/RNA-lipoprotein complex from living
cells—“the virtosome” [16, 17]. Of these sources, nucleo-
somes and virtosomes would appear to form major
components of CNAPS [16, 18].
Methodology (summarized in Fig. 1)
Blood samples
The quality and quantity of the nucleic acids extractable
from blood may depend upon the way in which the blood
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sample is handled after withdrawal from the patient given
the presence of nucleases in blood. Nucleic acids can be
extracted from whole blood, plasma and serum. Either the
blood can be held for various periods of time [19, 20] or the
serum/plasma are removed immediately from whole blood
and stored [21] or the nucleic acids are removed and stored
for further study. Cellular debris is removed by centrifuga-
tion either once or more so as to remove any cellular DNA/
RNA [22, 23]. Filtering has been used, but nucleic acids
can stick to the filter and so be lost from the material to be
analyzed. Furthermore, both centrifuging and filtering can
result in the removal of cells with surface DNA that have
been shown to be important in some diagnostic situations
[24]. Hence, both centrifugation and filtration could result
in a loss of nucleic acids and, to date, a standardized
method handling blood samples for all situations remains to
be evolved (Fig. 1).
Nucleic acid extraction from blood samples
Fleischhacker et al. [25] have compared the efficacy of
DNA extraction by testing three DNA isolation kits in two
different laboratories, in parallel. DNA isolation used spin
columns from diverse commercial suppliers—Qiamp DNA
Blood Midi Kit from Qiagen GmbH, Hilden, Germany (Q),
the NucleoSpin Kit from Macherey-Nagel, Hannover,
Germany (MN) and the MagNA Pure isolation system
from Roche Diagnostics, Mannheim, Germany (RD). Corre-
lations of plasma nucleosomes and cell-free DNA measured
by real-time PCR were comparable between the two
laboratories. Large differences in the amounts of cell-free
DNA were observed between the various isolation methods,
the RD isolation system giving the highest DNA yield
followed by the MN and Q systems. Most comparable results
with nucleosome ELISA were achieved using the Roche
system [25]. Interestingly, a comparison of seven isolation
methods for DNA from 2 ml serum from colorectal cancer
patients by Fong et al. [26] showed the QIAamp DNA Blood
Mini Kit with carrier RNA to be the best method with the
DNA fragments being of the order of 500 bp+. This
highlights the difficulties in finding the most suitable method
for the extraction of all DNA fragment sizes.
A recent development of the QIAamp circulating nucleic
acid kit working with larger volumes of either plasma or
serum may offer a more complete extraction kit [27].
A new development involving the rapid isolation and
detection of CNAPS isolated directly from whole blood
may offer a way of overcoming a number of the problems
involved in handling fresh blood samples [28]. A micro-
array dielectrophoretic system can both detect and isolate
high molecular weight DNA directly from whole blood
with levels of <260 ng ml−1DNA being detectable. The
method can also be applied to the isolation of nanoparticles
at <9.5×109 particles ml−1 [28].
Thus, although there are a number of commercial nucleic
acid isolations kits available, a greater amount and broader
range of fragment sizes appear to be isolated by either
salting out or phenol chloroform extraction or PAGE [29].
Nevertheless, at present, there is no strict consensus as to
which one method for the removal of CNAPS from blood
samples for analysis is valid for all nucleic acid assays and
the literature contains a wide variation of methodology.
Analytical methodology
Due to the relatively low levels of both DNA and RNA
circulating in plasma and serum, the methodology exploited
for diagnostic purposes is to isolate the nucleic acid and to
use either digital PCR [30] or quantitative RT-PCR [31] or
quantitative fluorescent PCR [32, 33] to increase the total
amount available for further analysis. More specific
analyses include the use of methylation specific PCR for
the methylation of e.g. promotors [34–36]. Nevertheless,
within in each PCR method there is room for possible
variation [37]. The fast, low-cost Recombinase Polymerase
Amplification methodology offered by TwistDx Ltd (www.
twistdx.co.uk) may offer a rapid and portable system that
can be used with CNAPS though this has yet to be
exploited. MALDI-TOF Mass Spectrometry offers an
additional way to provide quantitative, specific and sensi-
tive analysis of circulating RNA and DNA [38] as well as
rapid DNA mapping by fluorescent single molecule
detection [39].
Fig. 1 Illustration of the steps between obtaining a patient blood
sample and relating the isolated nucleic acids from plasma/serum and
leukocyte surfaces to a particular disorder so as to allow early
diagnosis, monitoring of treatment and prognosis for the patient. Some
examples of the analytical processes of the isolated nucleic acid
fragments are indicated
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Both high throughput parallel sequencing platforms
capable of reading 25 million bases of genetic code in 4 h
[40] and SOLiD technology for sequencing both whole
genomes and transcriptomes have also been recently devel-
oped. THE SOLiD system can deliver up to 60 GB of
mappable sequences and provide more than 400 million
sequence tags per instrument run [41]. These latter analytical
approaches handling large numbers of nucleic acid fragments
in very short times have permitted the introduction of the
analysis of CNAPS for specific cancer associated mutations,
gene methylation and the loss of heterozygosity as well as
extending the use of mRNAs and including microRNAs. The
exploitation of these approaches will be discussed at relevant
points in this review.
Circulating nucleic acids and oncology
The first proposed uses of circulating DNA were (a) as an
early marker for cancer through an increased total amount
circulating DNA and (b) in monitoring treatment when
DNA levels would return to normal upon treatment.
Unfortunately, there was no specific correlation between
the DNA fragments involved and a particular type of
cancer. There have been varying levels of success with this
approach.
Nucleosomes are one of the forms of DNA released into
the blood stream and the role of nucleosomes in the
detection of cancer has been reviewed [31]. However, in
general, they are less suitable for cancer diagnosis due to
elevated levels of nucleosomes in patients with benign
diseases. One possible instance when nucleosomes levels
correlate with tumor stage and the presence of metastases is
in gastrointestinal cancers. However, they do not do so
generally in other tumor types. Nevertheless, circulating
nucleosomes can be used to monitor cytotoxic therapy
when strongly decreasing levels are mainly found in
patients with disease remission whereas constantly high or
increasing values can be associated with progressive
disease during chemo- and radiotherapy. Therapy outcome
can be indicated by nucleosomal levels during the first
week of chemo- and radiotherapy in patients with lung,
pancreatic, and colorectal cancer as well as hematological
malignancies. Thus, nucleosomes may have a strong role to
play in therapy [31].
Similarly, the quantification of ALU repeats in the serum
of breast, colorectal and periampullary cancer patients
showed significantly higher values in sera of patients with
cancer as opposed to those from healthy controls [42].
Recently, microRNAs have been examined in plasma
and serum for use in fetal diagnosis [43, 44] and
myocardial infarct assessment [45] as well as a range of
cancers [46]. This approach is at an early stage of
development, but shows promising signs of yielding useful
marker molecules.
The cancers to be considered below will be confined to
lung, colorectal, breast, ovary, prostate, glioma and naso-
pharyngeal and human papilloma viral carcinomas. Other
cancers such as liver, kidney, head-and-neck have been less
well studied for their inclusion [47–50].
Lung cancer
The technology for circulating DNA was considered insuffi-
ciently well established for its use in the diagnosis of lung
cancer, Xue et al. [51] and Schmidt et al. [52] finding no
significant differences between lung cancer patients and
patients with a benign lung disease. Sozzi et al. [53] using
real-time PCR amplification of the human telomerase reverse
transcriptase gene (hTERT) in non-small cell lung cancer
(NSCLC) patients versus age-, sex- and smoking-matched
controls reported almost eight times the value detected in the
controls (24.3 v 3.1 ngml−1). They suggested that the plasma
DNA was a strong risk factor for lung cancer.
Tamkovich et al. [24] also found the average circulating
DNA concentration in plasma to be similar in healthy
donors and lung cancer patients. In the latter case, however,
measurement of the concentration of cell-surface-bound
circulating DNA showed that values for lung cancer
patients were significantly lower than those of healthy
donors (P<0.0001) and correlated with a poor prognosis of
tumor disease. Thus, individuals with poor prognosis of
tumor disease could be detected with 94% sensitivity and
50% specificity. Furthermore, similar results were found for
NSCLC patients [54] with the ratio of ß-actin gene to LINE
1 fragments in the cell surface DNA being elevated in
NSCLC patients. In addition, Wang et al. [55] identified
seven biomarkers from sputum analysis that might be used
for early lung cancer detection namely, loss of heterozy-
gosity of D9S286, D9S942, GATA49D12 and D13S170,
micro-satelite instability of D9S942 and methylation of
p16INK4a RARß.
The role in prognosis for CNAPS, in the case of NSCLC
has been exploited by Kimura et al. [56]. Cases of NSCLC
carrying the somatic mutation of epidermal growth factor
receptor (EGFR) were shown to be hyper-responsive to the
EGFR tyrosine kinase inhibitor, gefitinib (IRESSA). Prior
to commencing treatment, serum DNA from patients was
subjected to Scorpion Amplified Refractory Mutation
System technology to detect EGFR mutations.
The EGFR mutations were seen more frequently in
patients with a partial response than in those with either
stable or progressive disease (P=0.046). The median
progression-free survival was significantly longer in
patients with EGFR mutations than in patients without
EGFR mutations (200 versus 46 days; P=0.005). The
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median survival was 611 days in patients with EGFR
mutations as opposed to 232 days in patients without EGFR
mutations (P>0.05). Thus, patients with EGFR mutations
could be more successfully treated with gefitinib and hence
the analysis of CNAPS could aid in the selection of
NSCLC patients more readily receptive to this treatment.
More recently, the authors have shown that the success rate
of mutation detection of serum/plasma DNA can be
increased by about 70% if whole genome nucleosomes
together with other biomarkers present in serum such as
progastrin-releasing enzyme, neuron-specific enolase,
cytokeratin-19 fragments and carcinoembryonic antigen
can be useful in predicting the efficacy of the therapy
response [57]. Very preliminary studies on circulating
methylated APC and RAFFSIA gene sequences by duplex
real-time methylation-specific PCR were used to follow-up
NSCLC patients after operation. Although the levels of
APC and AFFSIA taken prior to operating could not be
used for prognostic purposes, those values taken shortly
after operating predicted non-reappearance in patients re-
examined after 6 months [58].
Colorectal cancer
Schwarzenbach et al. [59] showed that patients with
colorectal cancer had a wide range of DNA concentrations
in their blood (22 to 3,922 ngml−1 DNA) as compared to the
average concentration of cell-free DNA in the serum of
healthy donors (5–16 ng/ml) which appears to rule out the use
of DNA levels for the early detection of colorectal cancers.
K-ras mutations were exploited in the early analyses
though KRAS2 was found to be present in plasma and
serum of only 33% of colorectal cancer patients and absent
from a number of other patients [60, 61]. However, Ward
et al. [62] found that mutant K-ras present in that such
patients could represent an indication of adverse prognosis
as confirmed by Frattini et al. [63]. Following patients post-
surgery, the circulating DNA level was 25 times that of
normal individuals prior to surgery while post-surgery,
there was a decrease in DNA levels except in patients who
subsequently developed recurrences or metastases when the
DNA levels rose. A suggestion to improve the identifica-
tion of tumor related DNA in blood was to take blood
directly from the mesenteric/portal veins into which the
CNAPS flowed instead of from the peripheral veins [64].
The markers employed included 11micro-satellite frag-
ments corresponding to regions on six chromosomes
frequent for loss of heterozygosity in CRC the presence
of hypermethylated DNA for tumor suppressor genes
MGMT; p16; RAR-ß2; RASSFIA and APC. Circulating
DNA related to loss of heterozygosity and methylation was
more frequently detected in blood from the mesenteric/
portal veins than from the peripheral veins [64].
It would appear that circulating nucleosomes are not
reliable markers for colorectal cancer detection since they
are elevated also in the presence of both cancer and benign
diseases [65]. However, they may be used in monitoring
treatment with decreasing levels being found in patients
under remission. Increasing amounts of nucleosomes are
found with progressive disease under chemo- and radio-
therapy [65].
In considering nucleosomes for diagnostic purposes,
Deligezer et al. [66] have recently proposed that the ratio of
histone H3 lysine (9H3K9me3) to histone H4 lysine 9
(H4K20me3) in circulating nucleosomes might act as a
potential diagnostic biomarker for colorectal cancer. Prelim-
inary experiments have used trimethylation of H3K9me3 and
H4K20me3, two modifications involved in heterochromatin
formation, at the peri-centric heterochromatin of circulating
nucleosomes in blood plasma of the healthy individuals,
patients with colorectal cancer and multiple myeloma.
H3K9me3 was decreased in colorectal cancer and increased
in multiple myeloma while H4K20me3 levels were similar in
all study groups. Therefore, the H3K9me3/H4K20me3 ratio
could be used to normalize H3K9me3 concentrations. This
showed the ratio to be median 0.8 for colorectal patients as
against median 3.0 for healthy individuals and median 4.7
for multiple myeloma patients [66].
An alternative diagnostic approach, using microRNAs
(miRNAs), for colorectal cancer was developed by Schetter
et al. [67] and Ng et al. [68]. In the latter case, of a panel of
95 microRNAs, 5 were upregulated in both plasma and
serum from 25 colorectal cancer patients versus 20 healthy
individuals. miR-17-3P and miR-92 were significantly
elevated in the cancer patients. Plasma levels of these
markers were significantly reduced after surgery in ten of
the cancer patients. In addition miR-92 could be used to
differentiate between colorectal and gastric cancer and
irritable bowel disease patients.
Breast cancer
DNA levels appear to be greater in plasma from breast
cancer patients than from normal plasma donors. Zhong
et al. [69] isolated DNA from the plasma from breast cancer
patients, those with benign breast lesions and healthy
women. The DNA was quantified by real-time PCR for
the glyceraldehyde-3-phosphate dehydrogenase gene to
show 2,285, 1,368 and 1,489 genome equivalents ml−1.
Thus, there were significantly greater DNA levels for breast
cancer than for the controls. Furthermore, the DNA levels
were high in patients with lymph node involvement and
distant metastasis. Thus, these findings could have use in
both diagnosis and prognosis.
Unlike in the nucleosomal studies for colorectal cancer,
current investigations by Stoetzer et al. [70] found no
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absolute changes in nucleosomal levels in patients with
breast cancer receiving pre-operation neoadjuvant therapy
taken before commencing the first and second cycle and at
the end of chemotherapy.
Nevertheless, the applicability of cyclin D2 and RARβ2
methylated markers for the development of a breast tumor,
screening assay showed mixed results [71]. Forty two per
cent of the patients with primary diagnosis of breast
fibroadenoma showed an aberrant methylation of at least
one of the tested genes in the circulating DNA though 33%
of patients with breast lesions not diagnosed as fibroade-
noma also displayed methylation.
In contrast, the findings of Divella et al. [72] showed that
the level of the human hTERT gene in the plasma was
significantly different for breast cancer when compared to
fibroadenoma patients and healthy controls. (p<0.01),
showing a sensitivity of 50% and a specificity of 90% in
the ability to detect malignancy. The circulating hTERT
DNA was significantly different between the estrogen
receptor (ER)+/progesterone receptor (PgR)+ and the ER−/
PgR− patients (p+0.03). In addition, higher hTERT levels
were associated with higher human epidermal growth factor
receptor-2/neu expression. Given that hTERT was signifi-
cantly inversely correlated with the carbohydrate antigen
(CA) 15.3 serum level (P+0.001), circulating hTERT DNA
appears to have a better diagnostic value than CA 15.3 in
early breast cancer disease [72].
Interestingly, Contreros-Galindo et al. [73] have shown
evidence for high amounts of RNA from human endoge-
nous retrovirus K (HML-2) elements in the plasma from
both breast cancer and lymphoma patients as measured by
either reverse transcriptase PCR or nucleic acid base
sequence amplification. A drop in RNA levels occurs on
successfully treating the cancer.
Ovarian cancer
Kamat et al. [74] found that ovarian cancer patients had a
median DNA level of 10,113GEml−1, compared with patients
with benign ovarian neoplasms (median, 2,365 GE ml−1;
P<.0001) and controls (median, 1,912 GE ml−1, P<.0001).
Cell-free DNA >22,000 GE ml−1 was significantly associated
with decreased patient survival (P<.001). In addition,
preoperative cell-free DNA >22,000 GE ml−1 was an
independent predictor (P=.02) for disease-specific survival
and that cell-free DNA >22,000 GEml−1 was associated with
a 2.83-fold increased risk of death (P<.001).
In another approach, Wang et al. [75] indicated that a
DNA integrity index in plasma of cancer patients was
highly specific and sensitive for cancer detection. The test
is based on the concept that DNA fragments in serum and
plasma are longer than those of healthy individuals possibly
due to an inefficient nuclease activity. The amount of DNA
sized 400 bp and 100 bp was quantified in patients with
ovarian and other gynecological cancer. Significantly
higher proportions of long pieces were found in the cancer
patients than in both healthy controls and patients with
benign ovarian diseases [75]. This confirmed the high
potential of the integrity index for cancer detection and
prognosis [42, 47]. However, these results were not
confirmed by other workers throwing doubt on the general
use of the diagnostic capacity of DNA integrity index for
cancer [31]. At first sight it is their degree of differentiation
of the tumor types that may make this a difficult area for
CNAPS use. However, the fact that each histological form
has its own characteristic genetic defect may yield an
opening for the involvement of CNAPS through the
detection of specific DNA fragments [76].
Prostate cancer
Boddy et al. [77] found that cancer patients had a
significantly higher level of plasma DNA compared with
the control group, but that DNA levels in patients with a
benign biopsy were significantly higher than those in
patients with confirmed cancer. Using microsatellite DNA,
Müller et al. [78] found that prostate cancer (PC) patients
had a DNA mean value of 590 ng ml−1 (81–2,792 ng ml−1)
against 48 ng ml−1 (45–2,908 ng ml−1) for benign prostate
hyperplasia (BPH). Nevertheless, the range of DNA values
in each case would appear to limit their use in diagnosis. Of
the marker genes studied, loss of heterozygosity (LOH) was
highest at chromosomal regions 3p24 and 8p21 in PC
patients compared with BPH patients frequently showing
LOH at 6q21, 8p21, 9p21 and 11q22. The methylation
status of tumor-related genes RASSF1A, RARß2 and
GSTP1 together with genomic repeat sequences LINE 1
were also assessed [79] using methylation-specific PCR.
The combined classes of marker improved detection of
prostate cancer even in patients with normal prostate
specific antigen. A combination of both the DNA and PSA
assays gave a 89% sensitivity.
Studies on the profiles of GSTP1 gene methylation in the
extracellular DNA of PC patients revealed that such profiles
of patients differed from those displayed by healthy donors
and patients with BPH; hence, they could possibly be used
in early diagnosis. All the cytosines in the GSTP1 gene
promoter in the groups of healthy donors and patients with
BPH were unmethylated. However, the CpG dinucleotides
in GSTP1 gene promoter in all samples from PC patients
were methylated [80].
Telomere transcriptase mRNA is also a useful PC marker
[81]. There were mean values of 0.79 ng in PC patients,
0.29 in BPH patients and only 0.13 ng in healthy
individuals. Using a cut-off point of 0.35 ng, sensitivity
and specificity were 81% and 60%, respectively, Schwart-
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zenbach et al. [82] have suggested that the relationship
between circulating DNA and tumor cells (CTC) might be
exploited for early diagnosis and determination of tumor
stage in prostate cancer. An epithelial immunospot assay
was used to detect CTCs and a PCR-based fluorescence
microsatellite analysis exploiting a panel of 14 polymorphic
markers was used for the detection of allelic imbalances
(AI). Plasma DNA levels significantly correlated with the
subgroups of localized (M0) and metastasized (M1)
prostate cancer as well as the tumor stage. AI was detected
in the circulating plasma DNA from 45.0% of M0 and
58.5% of M1 patients. Seventy one percent of M0 and
92.0% of M1 patients harboured 1 to 40 CTCs in their
blood, correlating with the tumor stage [82].
Glioma
There have been few studies in this area. Kyle et al. [34]
determined the methylation status of the promoters for p16/
INK4a, MGMT, p73, and RARβ2 within glioma tissue and
plasma by methylation specific PCR. Blood was removed
from the patients prior to operation. Each methylated DNA
marker found in the plasma was also present in the intracranial
tumor. Patients with high-grade gliomas had high levels of
DNA in the plasma. Ninety percent of these primary brain
tumors contained methylated gene promoters and in over 60%
of the patients, the same methylated promoters present in the
tumor were also present in the plasma.
A similar approach was used by Lavon et al. [36] with
astrocytomas and oligodendrogliomas of various grades.
The median interval between surgery and serum sampling
was 1 month (range 0.5–168 months). Loss of heterozy-
gosity (LOH) in chromosomes 1p, 19q, and 10q was
assessed by PCR-based microsatellite analysis on DNA
extracted from whole blood, serum, and paraffin-embedded
tumor sections. The methylation status of O6-methyl
guanine methyltransferase (MGMT) and phosphatase and
tensin homologue promoters was studied by methylation-
specific PCR. Tumor-specific DNA was found in 80.5% of
astrocytic tumors and in all oligodendrogliomas whilst the
rate of serum detection did not differ between low- and
high-grade oligodendrogliomas. A statistically significant
tumor-serum concordance was found for MGMT methyla-
tion in both astrocytic tumors (83%; P<.001) and
oligodendroglial tumors (72%; P<.003) and for LOH of
10q (79%; P<.002) and 1p (62%; P<.03) in oligodendro-
gliomas. Statistically significant tumor-serum concordance
was found: (a) MGMT methylation in both astrocytic
tumors (83%; P<.001) and oligodendroglial tumors
(72%; P<.003): (b) LOH of 10q (79%; P<.002) and 1p
(62%; P<.03) in oligodendrogliomas. There was moderate
sensitivity and high specificity for both low- and high-grade
tumors.
Balaña et al. [83] also used this approach for monitoring
treatment showing a significantly high concordance of
methylation of MGMT in glioma tissue, and paired serum
DNA and the potential correlation with response and time
to progression. In the 16 patients treated with temozolamide
plus cisplatin, no significant correlation between MGMT
methylation status and response was observed, whereas in
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-treated
patients, a significant difference was observed in favour of
those with methylated MGMT. No correlation was ob-
served for p16, DAPK, or RASSF1A methylation between
response or time to progression.
Circulating nucleosomes in serum and cerebrospinal
fluid (CSF) from patients with glioblastoma, non-acute
neurological disorders, subarachnoid hemorrhage and non-
ruptured aneurysms were studied to determine if they could
be used in both diagnosis and prognosis [84]. In the case of
patients with glioblastoma treated by surgery and local
chemotherapy, levels of serum and CSF nucleosomes
increased moderately during the week after surgery. There
were no significant differences between pre-therapeutic
nucleosome levels in the various patient groups. Those
patients with glioblastoma developing cerebral edema had
CSF levels increased to almost 200—fold and reaching a
maximum on day 3 after surgery in contrast to patients
without edema. Thus monitoring CSF levels of nucleo-
somes in glioblastoma patients may indicated the develop-
ment of postoperative complications [84].
RNAs may also be exploited though, in this case, it is
the presence of RNA-containing exosomes released into the
blood from glioblastoma patients that have been assessed.
They have been shown to contain mRNA mutant/variants
and miRNA characteristic of gliomas. In particular, tumor-
specific EGFRvIII, containing a mutation specific for
glioblastoma was detected in the serum micro-vesicles of
seven out of twenty five glioblastoma patients [85].
Nasopharyngeal and human papilloma viral carcinomas
Viral DNAs have been found in CNAPS with the specific
DNAs of for Epstein Barr virus (EBV) in patients with
nasopharyngeal carcinoma [86, 87] and human papilloma
viral carcinoma in about half of cervical carcinoma patients
and hepatitis patients [88] having been identified. Naso-
pharyngeal carcinoma (NPC) is distinct from other head
and neck cancers by its epidemiology, histopathology, and
clinical characteristics. It is geographically endemic with an
incidence as high as 25 per 100,000 in South East Asia
[89]. Chan et al. [private communication] screened 1,318
subjects with no NPC. EBV viral capsid antigen (VCA-Iga)
was also assayed. Sixty-nine subjects had detectable EBV
DNA of which 19 were still positive 2 weeks later. On
clinical follow-up, three subjects were found to have NPC
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of which only one subject showed EBV VCA-Iga positiv-
ity. Thus, CNAPS EVB DNA may have a role to play in the
early diagnosis of NPC. Moreover, preliminary studies on
cervical cancer patients have indicated that plasma papillo-
ma virus DNA could be a useful marker for monitoring the
therapeutic response and disease progress in cervical cancer
[90].
Genometastasis
In spite of the wide range of mechanisms proposed for the
induction of metastases, the involvement of CNAPS in the
process is not included [91]. However, it is interesting to
review the data linking circulating nucleic acids to the
formation of metastases. The role of CNAPS in inducing
metastasis has been explored.
Early studies showed that a newly synthesized DNA/
RNA lipoprotein complex, the virtosome, was homeostati-
cally released from both normal and cancer cells [13, 16,
92–96]. The virtosomes could enter cells and change the
biology of these cells.
Thus SW 480 cell line, originating from a human colon
carcinoma, containing a point mutation of the K-ras gene
on both alleles, released the DNA/RNA-lipoprotein com-
plex containing the mutated K-ras gene. Transformed foci
appeared in NIH/3T3 cells that were cultured in the presence
of non-purified SW 480 cell supernatant containing the
virtosome complex. The presence of a mutated ras gene in
the transfected foci of the 3T3 cells was confirmed by
hybridization after PCR and by sequencing the PCR
product [96].
Similarly, on entering non-stimulated lymphocytes, the
virtosomes released from mouse tumor cell lines J774
cells (leukemia) and P497 cells (glial tumor) caused the
lymphocytes to synthesize DNA for cell division [13]. No
such DNA synthesis occurred if the virtosomes used were
obtained from non-dividing cells.
The data above of Skog et al. [85] also implicate RNA in
a similar manner.
The circulating nucleic acids in serum from patients with
colorectal cancer have recently been shown to be involved
in tumor induction. Thus, Garcia-Olmo et al. [97] cultured
NIH-3T3 cells in the presence of plasma from patients with
either K-ras-mutated colorectal tumors or from healthy
subjects. The plasma was either directly added to the
cultures or, to avoid plasma-cell contact, membranes with
0.4 µm pores were placed between the plasma and the cells
so acting as a filter. Human gene transfer occurred in most
cultures of NIH-3T3 cells, as shown by the presence of
human K-ras sequences, p53 sequences and ß-globin
encoding sequences. That the NIH-3T3 cells were onco-
genically transformed after being cultured with plasma
from colon cancer patients, was demonstrated by injecting
the transformed NIH-3T3 cells into NOD-SCID mice that
went on to develop tumors. The presence of an artificial
membrane containing 4 µm diameter pores placed between
the NIH-3T3 cells and the plasma gave similar results
showing that the transforming factor had a diameter of less
than 0.4 µm. A TEM study of the membranes from the
plasma experiments showed many structures of <0.4 µm
diameter were seen to pass through the pores of membrane.
This process has been termed Genometastasis [98, 99].
Serrano-Heras et al. [100] have suggested that the structures
passing through the pores are DNA-carrying exosomes.
However, the ability of the virtosomes released from tumor
cells to enter and stimulate DNA synthesis in non-
stimulated lymphocytes [13] and the presence of the
mutated K-ras gene DNA released from SW480 cells into
the culture medium to be present in the transformed NIH/
3T3 cells [96], implies that the virtosomes could also be
implicated in the metastatic process.
Conclusions & outlook
Fragments of DNA and the various forms of RNA are
clearly circulating in blood and there are important early
signs that they may be used as early diagnostic markers for
a number of disorders. Clearly, both DNA and RNA have
roles to play in personalized diagnosis and prognosis in
clinical oncology.
At present, clinical trials are in progress in the USA and
the UK for the use of CNAPS from maternal blood as a
minimally invasive method for examination of the fetus in
the first trimester e.g. for diagnosis of Down syndrome and
Rh factors. However, as can be seen above, the use of
CNAPS in personalized cancer detection is very much at
the experimental stage with many exciting prospects. Few
developments are at a stage where clinical trials can be held
though there are hopeful signs that the use of nucleosomes
to monitor cancer treatment, but not for diagnostic
purposes, can be established [25, 31, 57, 65, 84]. This
highlights the fact that, although many laboratories around
the world are engaged upon the applications of CNAPS in
personalized cancer studies and that a number of patents
have been obtained for various technical processes, there
are a limited number of laboratories working on any one
type of cancer and so progress to clinical use is relatively
slow.
Much more emphasis needs to be placed on improving
the quality of the methodology for consistency in usage
across laboratories before this approach can be put onto a
broad basis. This applies to the storage of blood samples,
the isolation of all nucleic acid fragments from the blood
and the method for analyzing those fragments. The new
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methodology [40, 41] for sequencing the nucleic acid
fragments in very short time periods allows for the
identification of a large range of markers that may be used
for any one cancer. However, time is still needed to
determine how best to handle so much data generated with
respect to cancer diagnosis and prognosis.
Attention is drawn to the evidence that some of the
nucleic acids in plasma and serum released from primary
tumors can act as messengers between cells and are
implicated in the initiation metastases. This poses questions
concerning the use for transfusion of blood taken from
individuals who, unknowingly, have cancer.
References
1. Mendel P, Métais P. Les acides nucléiques du plasma sanguine
chez l’homme. CR Acad Sci Paris. 1948;142:241–3.
2. Watson JD, Crick FH. A structure for deoxyribose nucleic acid.
Nature. 1953;171:737–8.
3. Wilkins MH, Stokes AR, Wilson HR. Molecular structure of
deoxypentose nucleic acids. Nature. 1953;171:738–40.
4. Sinsheimer RL. First steps toward a genetic chemistry. Science.
1957;125:1123–8.
5. Koffler D, Agnello V, Winchester R. The occurrence of single-
stranded DNA in the serum of patients with systemic lupus
erythrematosus and other diseases. J Clin Invest. 1973;52:198–204.
6. Tan EM, Schur PH, Carr RI, et al. Deoxyribonucleic acid (DNA)
and antibodies to DNA in the serum of patients with systemic
lupus erythrematosus. J Clin Invest. 1966;45:1732–40.
7. Rainer TH, Wong LK, Lam W, et al. Prognostic use of
circulating plasma nucleic acid concentrations in patients with
acute stroke. Clin Chem. 2003;49:562–9.
8. Lam NY, Rainer TH, Chan LY, et al. Time course of early and
late changes in plasma DNA in trauma patients. Clin Chem.
2003;49:1286–91.
9. Chiu TW, Young R, Chan LYS, et al. Plasma cell-free DNA as
an indicator of severity of injury in burn patients. Clin Hem Lab
Manag. 2006;44:13–7.
10. Gahan PB. Circulation nucleic acids in plasma and serum: roles
in diagnosis and prognosis in diabetes and cancer. Infect Disord
Drug Targets. 2008;8:100–8.
11. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum
of cancer patients and the effect of therapy. Cancer Res.
1977;37:646–50.
12. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of
the DNA found in the plasma of cancer patients. Oncology.
1989;46:318–22.
13. Anker P, Stroun M, Maurice P. Spontaneous release of DNA by
human blood lymphocytes as shown in an in vitro system.
Cancer Res. 1975;35:2375–82.
14. Rykova EY, Bryzgunova OE, Skvortsova TE, Tamkovich TN,
Senin IN, Laktionov PP, et al. Concentrations of circulating RNA
from healthy donors and cancer patients. Ann NY Acad Sci.
2006;1075:328–33.
15. Holford NC, Ramoutar A, Butt AN, et al. Normalization of
circulating nucleic acid results. Should we use β-actin? Ann NY
Acad Sci. 2008;1137:112–8.
16. Gahan PB, Stroun M. The biology of circulating nucleic acids in
plasma and serum. In: Rykova EY, Kikuchi Y, editors.
Extracellular nucleic acids. In Series “Nucleic Acids and
Molecular Biology” Springer Berlin; 2010, in press
17. Gahan PB, Stroun M. The virtosome—a novel cytosolic
informative entity & intercellular messenger. Cell Biochem
Funct; 2010, submitted
18. Gahan PB. Circulating nucleic acids in plasma and serum: roles
in diagnosis and prognosis. In: Golubnitschaja O, editor.
Predictive diagnostics and personalised treatment. Boston: Nova
Science Publishers; 2009.
19. Tsui NB, Ng EK, Lo YMD. Stability of endogenous and added
RNA in blood specimens, serum, and plasma. Clin Chem.
2002;48:1647–53.
20. Holford NC, Sandhu HS, Thakkar H, et al. Stability of β-Actin
mRNA in plasma. Ann NY Acad Sci. 2008;1137:108–11.
21. Board RE, Williams VS, Knight L, et al. Isolation and extraction
of circulating tumor DNA from patients with small cell lung
cancer. Ann NY Acad Sci. 2008;1137:98–107.
22. Page K, Powles T, Slade MJ, et al. The importance of careful
blood processing in isolation of cell free DNA. Ann NY Acad
Sci. 2006;1075:313.
23. Dovc-Drnovsek T, Emersic B, Rozman P. Optimisation of
purification of human cell-free mRNA from plasma. Ann NY
Acad Sci. 2008;1137:125–9.
24. Tamkovich SN, Litvjakov NV, Bryzgunova OE, et al. Cell-
surface-bound circulating DNA as a prognostic factor in lung
cancer. Ann NY Acad Sci. 2008;1137:214–7.
25. Fleischhacker M, Schmidt B, Weickmann S et al. Comparison of
nucleosomes and quantitative PCR using diverse DNA isolation
methods. In “Circulating Nucleic Acids in Plasma and Serum”.
Ed. PB Gahan. Berlin: Springer; 2010, in press
26. Fong SL, Zhang JT, Lim CK. Comparison of 7 methods for
extracting cell-free DNA from serum samples of colorectal
cancer patients. Clin Chem. 2009;55:587–9.
27. Horlitz M, Hartinger T, Graf S, et al. Yields of viral and
circulating cell-free nucleic acids using the QIAamp® circulating
nucleic acid kit. In: Gahan PB, editor. Circulating nucleic acids
in plasma and serum. Berlin: Springer; 2010. in press.
28. Krishnann R, Heller MJ. Rapid isolation and detection of cell
free circulating DNA and other disease biomarkers directly from
whole blood. In: Gahan PB, editor. Circulating nucleic acids in
plasma and serum. Berlin: Springer; 2010. in press.
29. Van der Vaart M, Pretorius PJ. A method for characterization of
total circulating DNA. Ann NY Acad Sci. 2008;1137:92–7.
30. Lo YMD, Lun FMF, Chan KCA, et al. Digital PCR for the
molecular detection of fetal chromosomal aneuploidy. Proc Natl
Acad Sci USA. 2007;104:13116–21.
31. Holdenrieder S, Burges A, Reich O, et al. DNA integrity in
plasma and serum of patients with malignant and benign
diseases. Ann NY Acad Sci. 2008;1137:162–70.
32. Ciriglian V, Voglino G, Marongiu A, et al. Rapid prenatal
diagnosis by QF-PCR: evaluation of 30, 000 consecutive clinical
samples and future applications. Ann NY Acad Sci. 2006;1075:
288–98.
33. Gole L, Adrianne F, Ee AM. Refining quantitative fluorescent
polymerase chain reaction for prenatal detection of X chromo-
somal anomalies in the major Southeast Asian populations.
Singapore Med J. 2008;49:1025–8.
34. Kyle D, Weaver MD, Stuart A, et al. Methylated tumor-specific
DNA as a plasma biomarker in patients with glioma. Cancer
Investig. 2006;24:35–40.
35. Sunami E, Shinozaki M, Higano CS, et al. Multimarker
circulating DNA assay for assessing blood of prostate cancer
patients. Clin Chem. 2009;55:559–67.
36. Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define
tumor-specific genetic and epigenetic markers in gliomas of
various grades. Neuro-Oncology. 2010;12:173–80.
37. Le Q-T, Jones CD, Yau T-K, et al. A comparison study of
different PCR assays in measuring circulating plasma epstein-
510 EPMA Journal (2010) 1:503–512
barr virus DNA levels in patients with nasopharyngeal carcino-
ma. Clin Cancer Res. 2005;11:5700–12.
38. Ding C, Lo YM. MALDI-TOF mass spectrometry for quantita-
tive, specific, and sensitive analysis of DNA and RNA. Ann NY
Acad Sci. 2006;1075:282–7.
39. Ming X, Phong A, Ha C, et al. Rapid DNA mapping by
fluorescent single molecule detection. Nucleic Acids Res.
2007;35(3):e16. doi:10.1093/nar/gkl1044.
40. Rogers YH, Ventner JC. Genomics: massively parallel sequenc-
ing. Nature. 2005;437:326–7.
41. Rossa WK, Sun CH, Akolekar R, et al. Maternal plasma DNA
analysis with massively parallel sequencing by ligation for
noninvasive prenatal diagnosis of trisomy 21. Clin Chem.
2010;56:459–63.
42. Umetani N, Kim J, Hiramats S, et al. Increased integrity of free
circulating DNA in sera of patients with colorectal. Clin Chem.
2006;52:1062–9.
43. Chim SSC, Shing TKF, Hung ECW. Detection and character-
ization of placental microRNAs in maternal plasma. Clin Chem.
2008;54:482–90.
44. Hung ECW, Chiu RWK, Lo YMD. Detection of circulating fetal
nucleic acids: a review of methods and applications. J Clin Path.
2009;62:308–13.
45. Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a
biomarker of myocardial injury. Clin Chem. 2009;55:1944–9.
46. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with
serum microRNAs on an oligonucleotide microarray. PLoS
ONE. 2009;14:e622.
47. Jiang WW, Zahurak M, Goldenberg D. Increased plasma DNA
integrity index in head and neck cancer patients. Int J Cancer.
2007;119:2673–6.
48. Daniotti M, Vallacchi V, Rivoltini L, et al. Detection of mutated
BRAFV600E variant in circulating DNA of stage III–IV
melanoma patients. Int J Cancer. 2007;120:2439–44.
49. Cheung ST, Fan ST, Lee YT, et al. Albumin mRNA in plasma
predicts post-transplant recurrence of patients with hepatocellular
carcinoma. Transplantation. 2008;85:81–7.
50. Gang F, Guorong L, An Z, et al. Prediction of clear cell renal cell
carcinoma by integrity of cell-free DNA in serum. Urology.
2010;75:262–5.
51. Xue X, Zhu YM, Woll PA. circulating DNA in lung cancer. Ann
NY Acad Sci. 2006;1075:154–64.
52. Schmidt B, Weickmann S, Witt C, et al. Integrity of cell-free
plasma DNA in patients with lung cancer and nonmalignant lung
disease. Ann NY Acad Sci. 2008;1137:207–13.
53. Sozzi G, Conte D, Leon ME. Quantification of free circulating
DNA as a diagnostic marker in lung cancer. J Clin Oncol.
2003;21:3902–8.
54. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al.
Concentration and distribution of single-copy β-actin gene and
LINE-1 repetitive elements in blood of lung cancer patients. In:
Gahan PB, editor. Circulating nucleic acids in plasma and serum.
Berlin: Springer; 2010. in press.
55. Wang YC, Hsu HS, Chen TP, et al. Molecular diagnostic markers
for lung cancer in sputum and plasma. Ann NY Acad Sci.
2006;1075:179–84.
56. Kimura H, Kasahara K, Kawaishi M, et al. Detection of
epidermal growth factor receptor mutations in serum as a
predictor of the response to gefitinib in patients with non-small
cell lung cancer. Clin Cancer Res. 2006;13:3915–21.
57. Holdenreider S, van Pawel J, Duell T, et al. Circulating nucleosomes
and oncogenic biomarkers in monitoring chemotherapy of small
cell lung cancer. In: Gahan PB, editor. Circulating nucleic acids in
plasma and serum. Berlin: Springer; 2010. in press.
58. Ding Q, Mu Y, Pan S, et al. Plasma DNA methylation analysis in
predicting short-term recurrence of surgical patients with non-
small cell lung cancer (NSCLC). In: Gahan PB, editor.
Circulating nucleic acids in plasma and serum. Berlin: Springer;
2010. in press.
59. Schwarzenbach H, Stoehlmacher J, Pantel K, et al. Detection and
monitoring of cell-free DNA in blood of patients with colorectal
cancer. Ann NY Acad Sci. 2008;1137:190196.
60. Sorenson GD. A review of studies on the detection of mutated
KRAS2 sequences as tumor markers in plasma/serum of patients
with gastrointestinal cancer. Ann NY Acad Sci. 2000;906:13–6.
61. Su YH, Wang M, Brenner DE, et al. Detection of mutated K-ras
in urine, plasma and serum of patients with colorectal carcinoma
or adenomatous polyps. Ann NYAcad Sci. 2008;1137:197–206.
62. Ward R, Sheehan C, Norrie M, et al. Factors influencing the
detection of mutant K-ras in the serum of patients with colorectal
cancer. Ann NY Acad Sci. 2000;906:17–8.
63. Frattini M, Gallino G, Signoroni S, et al. Quantitative analysis of
plasma DNA in colorectal cancer patients. Ann NY Acad Sci.
2006;1075:185–90.
64. Taback B, Saha S, Hoon DSB. Comparative analysis of
mesenteric and peripheral blood circulating tumor DNA in
colorectal cancer. Ann NY Acad Sci. 2006;1075:197–203.
65. Holdenrieder S, Nagel D, Schalhorn A. Clinical relevance of
circulating nucleosomes in cancer. Ann NY Acad Sci.
2008;1137:180–9.
66. Deligezer U, Akisik EZ, Akisik EE, et al. H3K9me3/H4K20me3
ratio in circulating nucleosomes as potential biomarker for
colorectal cancer. In: Gahan PB, editor. Circulating nucleic acids
in plasma and serum. Berlin: Springer; 2010. in press.
67. Schetter AJ, Harris CC. Plasma microRNAs: potential biomarker
for colorectal cancer? Gut. 2009;58:1318–9.
68. Ng EKO, Chong WWS, Jin H, et al. Differential expression of
microRNAs in plasma of patients with colorectal cancer: a
potential marker for colorectal cancer screening. Gut.
2009;58:1375–81. doi:10.1136/gut.2008.167817.
69. Zhong XY, Ladewig A, Schmid S, et al. Elevated level of cell-
free plasma DNA is associated with breast cancer. Arch Gynecol
Obstet. 2007;276:327–31.
70. Stoetzer OJ, Fersching DMI, Holdenrieder S. Circulating
nucleosomes and DNAse in breast cancer patients during
neoadjuvant chemotherapy. In: Gahan PB, editor. Circulating
nucleic acids in plasma and serum. Berlin: Springer; 2010. in
press.
71. Rykova EY, Tsvetovskaya GA, Sergeeva GI, et al. Methylation-
based analysis of circulating DNA for breast tumor screening.
Ann NY Acad Sci. 2008;1137:232–5.
72. Divella R, Tommasi S, Lacalamita R, et al. Circulating hTERT
DNA in Early Breast Cancer. Anticancer Res. 2009;29:2845–9.
73. Contreros-Galindo R, Kaplan MH, Leissner P, et al. Human
endogenous retrovirus K (HML-2) elements in the plasma of people
with lymphoma and breast cancer. J Virol. 2008;82:9329–36.
74. Kamat A, Baldwi M, Urbauer D, et al. Plasma cell-free DNA in
ovarian cancer. Cancer. 2010. doi:10.1002/cncr.24997.
75. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA
integrity in cancer patients. Cancer Res. 2003;63:3966–8.
76. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol-Mech.
2009;4:287–313.
77. Boddy JL, Gal S, Malone PR, et al. Prospective study of
quantitation of plasma DNA levels in the diagnosis of
malignant versus benign prostate disease. Clin Cancer Res.
2005;11:1394–9.
78. Muller I, Urban K, Pantel K, et al. Comparison of genetic
alterations detected in circulating microsatellite DNA in blood
plasma samples of patients with prostate cancer and benign
hyperplasia. Ann NY Acad Sci. 2006;1075:222–9.
79. Hoon DSB, Shinozaki M, Higano CS, et al. Circulating DNA
serum biomarkers of different forms utility in evaluating prostate
EPMA Journal (2010) 1:503–512 511
cancer patients. In: Gahan PB, editor. Circulating nucleic acids in
plasma and serum. Berlin: Springer; 2010. in press.
80. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, et al.
Methylation-specific sequencing of GStP1 gene promoter in
circulating/extracellular DNA from blood and urine of healthy
donors and prostate cancer patients. Ann NY Acad Sci. 2008;
1137:222–5.
81. Dasi F, Martinez-Rodes P, March JA, et al. Real-time quantifi-
cation of human telomerase reverse transcriptase mRNA in the
plasma of patients with prostate cancer. Ann NY Acad Sci.
2006;1075:204–10.
82. Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cell-free
tumor DNA in blood plasma as a marker for circulating tumor
cells in prostate cancer. Clin Cancer Res. 2009;15:1032–8.
83. Balaña C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA
methyltransferase methylation in serum and tumor DNA predicts
response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to
temozolamide plus cisplatin in glioblastoma multiforme. Clin
Cancer Res. 2003;9:1461–8.
84. Holdenrieder S, Spuler A, Tischinger M, et al. Presence of
nucleosomes in cerebrospinal fluid of glioblastoma patients—
potential for therapy monitoring. In: Gahan PB, editor. Circulating
nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
85. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma micro-
vesicles transport RNA and proteins that promote tumor growth
and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:
1470–6.
86. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free
Epstein-Barr virus DNA in plasma of patients with nasopharyn-
geal carcinoma. Clin Cancer Res. 1999;59:1188–91.
87. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma.
Ann Oncol. 2002;13:1007–15.
88. Yang HJ, Liu VW, Tsang PC, et al. Quantification of human
papilloma virus DNA in the plasma of patients with cervical
cancer. Int J Gynecol. 2004;14:93–910.
89. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of
nasopharyngeal carcinoma. Mol Pathol. 2000;53:248–54.
90. Yang HJ, Liu VW, Tsang PC, et al. Quantification of human
papilloma virus DN in the plasma of patients with cervical
carcinoma. Int J Gynecol Cancer. 2004;14:903–10.
91. Adams DH, Gahan PB. Stimulated and non-stimulated rat spleen
cells release different DNA-Sciences Genève complexes. Differ-
entiation. 1982;22:47–52.
92. Adams DH, Gahan PB. The DNA extruded by rat spleen cells in
culture. Int J Biochem. 1983;15:547–52.
93. Stroun M, Anker P, Gahan PB, Henri J. Spontaneous release of
newly synthesized DNA from frog auricles. Arch Sci (Genève).
1977;30:229–42.
94. Anker P, Lyautey J, Lefort F, Lederrey C, Stroun M. Transfor-
mation of NIH/3T3 cells and SW 480 cells displaying K-ras
mutation. CR Acad Sci III. 1994;10:869–74.
95. Adams DH, Diaz N, Gahan PB. In vitro stimulation by tumor
cell media of [3H]thymidine incorporation by mouse spleen
lymphocytes. Cell Biochem Funct. 1997;15:119–26.
96. García-Olmo DC, Domínguez C, García-Arranz M, et al. Cell-
free nucleic acids circulating in the plasma of colorectal cancer
patients induce the oncogenic transformation of susceptible
cultured cells. Cancer Res. 2010;70:560–7.
97. García-Olmo D, García-Olmo DC, Ontañón J, et al. Tumor DNA
circulating in the plasma might play a role in metastasis. The
hypothesis of genometastasis. Histol Histopathol. 1999;14:
1159–64.
98. García-Olmo D, García-Olmo DC, Ontañón J, et al. Horizontal
transfer of DNA and the “genometastasis hypothesis”. Blood.
2000;95:724–5.
99. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating
nucleic acids in plasma and serum (CNAPS) and its relation to
stem cells and cancer metastasis: state of the issue. Histol
Histopathol. 2004;19:575–83.
100. Serrano-Heras G, García-Olmo D, García-Olmo DC. Micro-
vesicles circulating in plasma of rats contain DNA. Are these
small vesicles a main source of cell-free DNA in plasma? In:
Gahan PB, editor. Circulating nucleic acids in plasma and serum.
Berlin: Springer; 2010. in press.
512 EPMA Journal (2010) 1:503–512
